High-level Expression of Rad51 is an Independent Prognostic Marker of Survival in Non-small-cell Lung Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Jun 16

PMID 15956972

Citations 73

Authors

G-B Qiao

Y-L Wu

X-N Yang

W-Z Zhong

D Xie

X-Y Guan

D Fischer

H-C Kolberg

S Kruger

H-W Stuerzbecher

Affiliations

Soon will be listed here.

Abstract

High-level expression of Rad51, a key factor in homologous recombination, has been observed in a variety of human malignancies. This study was aimed to evaluate Rad51 expression to serve as prognostic marker in non-small-cell lung cancer (NSCLC). A total of 383 non-small-cell lung tumours were analysed immunohistochemically on NSCLC tissue microarrays. High-level Rad51 expression was observed in 29.4% (100 out of 340) of cases. Patients whose tumours displayed high-level Rad51 expression showed a significantly shorter median survival time of 19 vs 68 months (P<0.0001, log-rank test). Similarly T status, N status, M status, clinical stage and histological tumour grade were significant prognostic markers in univariate Cox survival analysis. Importantly, Rad51 expression (P<0.0001) together with tumour differentiation (P<0.009), clinical stage (P=0.004) and N status (P=0.0001) proved to be independent prognostic parameters in multivariate analysis. Rad51 expression predicted the outcome of squamous cell cancer as well as adenocarcinoma of the lung. Our results suggest that Rad51 expression provides additional prognostic information for surgically treated NSCLC patients. We hypothesise that the decreased survival of NSCLC patients with high-level expression of Rad51 is related to an enhanced propensity of tumour cells for survival, antiapoptosis and chemo-/radioresistance.

Citing Articles

Dual-specificity phosphatase 23 functions as a promising prognostic biomarker in non-small cell lung cancer.

Keum S, Lee Y, Kim J, Rhee S Genes Genomics. 2024; 47(3):321-329.

PMID: 39693003 DOI: 10.1007/s13258-024-01604-9.

Contribution of Radiation Sensitive Protein 51 Genotypes to Pterygium Risk in a Taiwanese Population.

Hsia N, Hu P, Chuang C, Mong M, Chen H, Tsai C In Vivo. 2024; 38(5):2197-2204.

PMID: 39187312 PMC: 11363769. DOI: 10.21873/invivo.13683.

Human Rad51 Protein Requires Higher Concentrations of Calcium Ions for D-Loop Formation than for Oligonucleotide Strand Exchange.

Renodon-Corniere A, Mikawa T, Kuwabara N, Ito K, Levitsky D, Iwasaki H Int J Mol Sci. 2024; 25(7).

PMID: 38612444 PMC: 11011376. DOI: 10.3390/ijms25073633.

mRNA Expression and Methylation of the , , , , and Genes in Gastric Adenocarcinoma.

Padua J, Mariano C, Fabro A, Lizarte Neto F, Zuliani R, Sares C Biomark Insights. 2024; 19:11772719231225206.

PMID: 38293680 PMC: 10826385. DOI: 10.1177/11772719231225206.

Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.

Khamidullina A, Abramenko Y, Bruter A, Tatarskiy V Int J Mol Sci. 2024; 25(2).

PMID: 38279263 PMC: 10816012. DOI: 10.3390/ijms25021263.

References

Vispe S, Cazaux C, Lesca C, Defais M . Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998; 26(12):2859-64. PMC: 147643. DOI: 10.1093/nar/26.12.2859. View

Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J . Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997; 88(2):265-75. DOI: 10.1016/s0092-8674(00)81847-4. View

Brundage M, Davies D, Mackillop W . Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122(3):1037-57. DOI: 10.1378/chest.122.3.1037. View

Sharan S, Morimatsu M, Albrecht U, Lim D, Regel E, Dinh C . Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997; 386(6627):804-10. DOI: 10.1038/386804a0. View

Han H, Bearss D, Browne L, Calaluce R, Nagle R, Von Hoff D . Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002; 62(10):2890-6. View

Mountain C . Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-7. DOI: 10.1378/chest.111.6.1710. View

Henning W, Sturzbecher H . Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology. 2003; 193(1-2):91-109. DOI: 10.1016/s0300-483x(03)00291-9. View

Sobin L . The World Health Organization's Histological Classification of Lung Tumors: a comparison of the first and second editions. Cancer Detect Prev. 1982; 5(4):391-406. View

Ohnishi T, Taki T, Hiraga S, Arita N, Morita T . In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun. 1998; 245(2):319-24. DOI: 10.1006/bbrc.1998.8440. View

10.

Kronqvist P, Kuopio T, Collan Y . Morphometric grading of invasive ductal breast cancer. I. Thresholds for nuclear grade. Br J Cancer. 1998; 78(6):800-5. PMC: 2062958. DOI: 10.1038/bjc.1998.582. View

11.

Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S . Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000; 88(6):907-13. DOI: 10.1002/1097-0215(20001215)88:6<907::aid-ijc11>3.0.co;2-4. View

12.

Yanagisawa T, Urade M, Yamamoto Y, Furuyama J . Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10. Oral Oncol. 1999; 34(6):524-8. DOI: 10.1016/s1368-8375(98)00045-1. View

13.

Sonoda E, Sasaki M, Buerstedde J, Bezzubova O, Shinohara A, Ogawa H . Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 1998; 17(2):598-608. PMC: 1170409. DOI: 10.1093/emboj/17.2.598. View

14.

Sturzbecher H, Donzelmann B, Henning W, Knippschild U, Buchhop S . p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 1996; 15(8):1992-2002. PMC: 450118. View

15.

Carney D . Lung cancer--time to move on from chemotherapy. N Engl J Med. 2002; 346(2):126-8. DOI: 10.1056/NEJM200201103460211. View

16.

Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L . DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000; 19(23):2791-5. DOI: 10.1038/sj.onc.1203578. View

17.

Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M . Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A. 1996; 93(13):6236-40. PMC: 39005. DOI: 10.1073/pnas.93.13.6236. View

18.

Buccheri G, Ferrigno D . Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994; 7(7):1350-64. DOI: 10.1183/09031936.94.07071350. View

19.

Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T . Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002; 62(1):219-25. View

20.

Xia S, Shammas M, Shmookler Reis R . Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol. 1997; 17(12):7151-8. PMC: 232572. DOI: 10.1128/MCB.17.12.7151. View